RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Research and Development

A collection of news and information related to Research and Development published by this site and its partners.

Top Research and Development Articles

Displaying items 12-22
  • Pfizer's interest in AstraZeneca worries Maryland

    Pfizer's interest in AstraZeneca worries Maryland
    Research labs closed by pharmaceutical giant Pfizer dot the country: Illinois. Michigan. New Jersey. New York. North Carolina. Maryland officials don't want this state to join that list. After Pfizer declared its desire to buy AstraZeneca — which...
  • STX goes global, expands into ice hockey

    STX goes global, expands into ice hockey
    Athletes associate STX with lacrosse, but the Baltimore-based brand began appearing last month in stores on ice hockey sticks and plans to launch a line of men's field hockey sticks in the United Kingdom. For the 44-year-old inventor of the modern...
  • Letters: Paying big bucks to Big Pharma

    Re "Prices of new drugs tough to take," March 10 I understand the necessity for drug companies to recoup research and development costs. But in regard to a medication that can cure hepatitis C, a spokesman for the maker of one drug that costs about $1,...
  • A plan for building Maryland's economy [Commentary]

    A plan for building Maryland's economy [Commentary]
    Earlier this General Assembly session, we joined together to announce a transformational economic development commission, a part of a joint economic development agenda that builds on the strategic investments Gov. Martin O'Malley and the legislature...
  • Lupin name on Baltimore building marks drug company's expansion

    Lupin name on Baltimore building marks drug company's expansion
    Lupin Pharmaceuticals, Inc. has placed its name in lights over the Inner Harbor, a mark of the Indian drug manufacturer's growing presence since the company located its U.S. headquarters in Baltimore more than a decade ago. Lupin, which today sells...
  • Sen. Tim Kaine tours Newport News Shipbuilding and NASA Langley in Hampton

    Sen. Tim Kaine tours Newport News Shipbuilding and NASA Langley in Hampton
    Newport News Shipbuilding and NASA Langley Research Center in Hampton are feeling the pinch of budget uncertainty in Washington, but Sen. Tim Kaine says Congress might clear that up in the coming weeks. The Virginia Democrat toured both facilities...
  • Allergan stock climbs amid $46-billion bid

    Canadian company Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman moved forward with their plans to acquire Botox maker Allergan Inc., offering shareholders about $46 billion and touching off what could be a contentious fight....
  • Ackman, Valeant partner in bid to buy Botox maker Allergan

    Activist investor Bill Ackman is partnering with a Canadian pharmaceutical company in an effort to buy Allergan Inc., the Irvine company that makes the popular wrinkle treatment Botox. Ackman and Valeant Pharmaceuticals International Inc. have already...
  • Drug maker Merck laying off 8,500 in strategy overhaul

    Drug maker Merck laying off 8,500 in strategy overhaul
    Merck & Co., the second-largest drug maker by sales, said Tuesday it will lay off 8,500 employees in a strategy overhaul to revamp its research and development efforts.  That's on top of a previous announcement that the Whitehouse Station, N.J.-based...
  • Pentagon makes costly foray into biodefense drug business

    WASHINGTON — Despite intense pressure to hold down federal spending, the Defense Department is launching a high-priced effort to create its own production pipeline for vaccines and biodefense drugs — an initiative that defies the advice of...
  • Herbalife takes another bite out of Bill Ackman

    Followers of Herbalife, the Los Angeles peddler of nutritional supplements, know it's actually two stories rolled into one. One is the story of how a company with a questionable business model, overhyped products, and an almost invisible research and...